By Brendan Pierson (Reuters) - A federal judge in Texas on Thursday blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain...
Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,”...
-- Landmark ZUMA-7 Study OS Data Reach Maturity Per Protocol, 5 Years After 1st Patient Randomized -- Kite, a Gilead Company (Nasdaq: NASDAQ:GILD), today announced the primary...
The pharmaceutical industry is a top investment option, with the sector experiencing rapid growth in recent years. The COVID-19 pandemic has also shifted the market focus to the...
Solid earnings lift US stocks to multi-month highs despite hawkish Fed soundbitesYen slips further as markets unrattled by China flexing its military muscle over TaiwanPound edges...
S&P 500 EPS growth for Q2 is set to come in at 6.0%, the lowest level since Q4 2020 Some highly anticipated names reported last week, with big EPS misses from big...
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Average | 88.8636 (+7.1033% Upside) |
| High | 115.0000 |
| Low | 63.0000 |
| Price | 82.9700 |
| No. of Analysts | 22 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 207.46 | 207.79 | 197.20 | +12.18 | +6.24% | 168.62M | NASDAQ | |||
| 164.90 | 165.00 | 161.91 | +2.54 | +1.56% | 67.09M | NASDAQ | |||
| 62.03 | 62.25 | 61.87 | +0.18 | +0.29% | 14.06M | NYSE | |||
| 211.94 | 212.17 | 206.77 | +4.10 | +1.97% | 25.22M | NASDAQ | |||
| 103.73 | 103.89 | 101.04 | +2.84 | +2.81% | 35.75M | NASDAQ | |||
| 289.27 | 289.27 | 283.00 | +5.22 | +1.84% | 32.09M | NASDAQ | |||
| 40.80 | 40.83 | 40.28 | +0.42 | +1.04% | 22.83M | NYSE | |||
| 98.01 | 98.36 | 95.27 | +0.13 | +0.13% | 55.43M | NASDAQ | |||
| 103.29 | 103.49 | 101.95 | +1.29 | +1.26% | 55.70M | NASDAQ | |||
| 166.04 | 166.68 | 164.29 | +3.37 | +2.07% | 1.51M | NASDAQ | |||
| 277.77 | 278.34 | 271.05 | +3.94 | +1.44% | 42.98M | NASDAQ | |||
| 8.45 | 8.48 | 8.08 | +0.30 | +3.68% | 26.03M | NYSE | |||
| 104.00 | 104.19 | 101.44 | +2.68 | +2.65% | 27.08M | NASDAQ | |||
| 47.94 | 48.13 | 45.95 | +1.43 | +3.07% | 13.46M | NYSE | |||
| 10.27 | 10.275 | 10.27 | 0.00 | 0.00% | 0.00 | NYSE |